Europe Continuous Bioprocessing Market
The Europe Continuous Bioprocessing Market is expected to grow at a CAGR of 19.1% from 2023 to 2030 to reach $206.1 million by 2030. Continuous manufacturing is an emerging trend spanning various industries. From automotive to paper, businesses are embracing continuous manufacturing to enhance efficiency and bolster profits. The shift from batch to continuous manufacturing is gaining traction in the biopharmaceuticals sector due to the surge in demand for intricate therapies and heightened market competition.
Download Presentation
Please find below an Image/Link to download the presentation.
The content on the website is provided AS IS for your information and personal use only. It may not be sold, licensed, or shared on other websites without obtaining consent from the author. Download presentation by click this link. If you encounter any issues during the download, it is possible that the publisher has removed the file from their server.
E N D
Presentation Transcript
Europe Continuous Bioprocessing Market to reach $206.1 million by 2030 Europe Continuous Bioprocessing Market by Product (Filtration, Chromatography, Centrifuges, Consumables), Application (Commercial {Vaccines, Monoclonal Antibodies}, R&D), End User (Pharmaceuticals, Biotechnology, CROs) - Forecast to 2030, published by Meticulous Research, the Europe continuous bioprocessing market is expected to grow at a CAGR of 19.1% from 2023 to reach $206.1 million by 2030. Download Free Report Sample Now: https://www.meticulousresearch.com/download- sample- report/cp_id=5605?utm_source=pdf&utm_medium=social+&utm_campaign=product&utm_ content=18-04-2024 Continuous bioprocessing is increasingly being adopted in biopharmaceutical manufacturing due to its agility, flexibility, efficiency, and robustness. This approach streamlines processes by minimizing steps, employing smaller facilities and equipment, and enhancing product quality for real-time release. Currently, continuous bioprocessing is predominantly utilized in small-scale perfusion. However, its benefits, including cost-effectiveness and product quality, are expected to drive its adoption in large-scale biopharmaceutical production in the forthcoming years. Continuous bioprocessing encompasses various components, including instruments and consumables like filtration, chromatography, centrifugation, bioreactors, incubator/shakers, sterilizers, cell culture media, buffers, and reagents. The growth of this market is attributed to factors such as recent product launches and advances in the continuous bioprocessing space, gradual adoption of continuous manufacturing, and initiatives supporting the adoption of biopharmaceuticals. Furthermore, the shift towards bioprocessing 4.0 and the rising adoption of personalized medicines are expected to provide significant market growth opportunities. Browse in depth: https://www.meticulousresearch.com/product/europe-continuous- bioprocessing-market- 5605?utm_source=pdf&utm_medium=social+&utm_campaign=product&utm_content=18- 04-2024 Supportive Government Initiatives Across the European Region to Drive the Market s Growth Governments across several European nations are undertaking initiatives to promote the adoption of continuous bioprocessing due to their benefits, such as consistent product quality, enhanced productivity, reduced equipment size, streamlined process flow, and low operating and capital expenses. For instance: The report also includes an extensive assessment of the key growth strategies adopted by leading market players in the past four years. In recent years, the Europe continuous bioprocessing market has witnessed numerous organic and inorganic strategic developments.
The key players profiled in this market study are 3M Company (U.S.), Cytiva (U.S.), Thermo Fisher Scientific Inc. (U.S.), Merck KGaA (Germany), Sartorius AG (Germany), Repligen Corporation (U.S.), Eppendorf AG (Germany), Applikon Biotechnology (Netherlands), Pall Corporation (U.S.), Solida Biotech GmBH (Germany), Electrolab Biotech Limited (U.K.), Biowest (France), and Bionet (U.S.). Download request sample report here: https://www.meticulousresearch.com/request- sample- report/cp_id=5605?utm_source=pdf&utm_medium=social+&utm_campaign=product&utm_ content=18-04-2024 Based on application, in 2023, the R&D segment is projected to register a higher CAGR during the forecast period. The growing interest in clinical studies for monoclonal antibodies, gene therapies, and vaccines and the focus on increasing R&D scale through government initiatives support the growth of the R&D segment. For instance, in 2021, the government of Ireland allocated USD 975.2 billion (EUR 869.2 billion) for research and development to software, medical devices, manufacturing, and pharmaceutical companies. Furthermore, in 2021, Medical Research Agency (Poland) launched government funding of USD 73.3 million (PLN 300 million) to produce vaccines in Poland. Based on geography, the market in Germany is projected to register the highest growth rate during the forecast period (2023-2030). The market growth in Germany is driven by the rise in pharmaceutical exports, government grants, growing immunization efforts, increased funding for biotech and biopharmaceutical firms, and the expansion of production capacities among biopharmaceutical companies to meet the growing demand for biologics. Quick buy: https://www.meticulousresearch.com/Checkout/86338782?utm_source=pdf&utm_medium =social+&utm_campaign=product&utm_content=18-04-2024 Contact Us: Meticulous Research Email-sales@meticulousresearch.com Contact Sales- +1-646-781-8004 Connect with us on LinkedIn-https://www.linkedin.com/company/meticulous- research
